References

  1. Allolio B, Fassnacht M. Clinical review: Adrenocortical carcinoma: Clinical update. J Clin Endocrinol Metab. 2006; 91(6): 2027-2037. PubMed | Google Scholar

  2. Deckers S, Derdelinckx L, Col V, Hamels J & Maiter D. Peritoneal carcinomatosis following laparoscopic resection of an adrenocortical tumor causing primary hyperaldosteronism. Hormone Research. 1999; 52: 97-100. PubMed | Google Scholar

  3. Calvo-Romero JM, Ramos-Salado JL. Recurrence of adrenal aldosterone-producing adenoma. Postgrad Med J. 2000; 76(893): 160-161. PubMed | Google Scholar

  4. Fassnacht M, Kroiss M, Allolio B. Update in adrenocortical carcinoma. J Clin Endocrinol Metab. 2013; 98(12): 4551. PubMed | Google Scholar

  5. National Institutes of Health. NIH state-of-the-science statement on management of the clinically inapparent adrenal mass ("incidentaloma"). NIH Consens State Sci Statements. 2002; 19(2): 1-25. PubMed | Google Scholar

  6. Weiss LM. Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors. Am J Surgical Pathology. 1984; 8(3): 163-169. PubMed | Google Scholar

  7. Weiss LM, Medeiros LJ, Vickery AL Jr. Pathologic features of prognostic significance in adrenocortical carcinoma. Am J Surgical Pathology. 1989 Mar; 13(3): 202-6. PubMed | Google Scholar

  8. Allolio B, Hahner S, Weismann D, Fassnacht M. Management of adrenocortical carcinoma. Clinical Endocrinology. 2004; 60(3): 273-87. PubMed | Google Scholar

  9. Freire DS, Siqueira SA, Zerbini MC, Wajchenberg BL, Corrêa-Giannella ML, Lucon AM et al. Development and internal validation of an adrenal cortical carcinoma prognostic score for predicting the risk of metastasis and local recurrence. Clinical Endocrinology. 2013; 79(4): 468-475. PubMed | Google Scholar

  10. Seccia TM, Fassina A, Nussdorfer GG, Pessina AC, Rossi GP. Aldosterone-producing adrenocortical carcinoma: an unusual cause of conn's syndrome with an ominous clinical course. Endocrine Related Cancer. 2005; 12(1): 149-159. PubMed | Google Scholar

  11. Simon G, Pattou F, Mirallié E, Lifante JC, Nominé C, Arnault V, de Calan L, Caillard C, Carnaille B, Brunaud L, Laplace N, Caiazzo R, Blanchard C. Surgery for recurrent adrenocortical carcinoma: a multicenter retrospective study. Surgery. 2017; 161(1): 249-256. PubMed | Google Scholar

  12. Luton JP, Cerdas S, Billaud L, Thomas G, Guilhaume B, Bertagna X, Laudat MH, Louvel A, Chapuis Y, Blondeau P et al. Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. New England Journal of Medicine. 1990; 322(17): 1195-1201. PubMed | Google Scholar

  13. Icard P, Goudet P, Charpenay C, Andreassian B, Carnaille B, Chapuis Y, Cougard P, Henry JF, Proye C. Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons Study Group. World Journal of Surgery. 2001; 25(7): 891-897. PubMed | Google Scholar

  14. Fassnacht M, Terzolo M, Allolio B et al. Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med 2012; 366: 2189-2197. Google Scholar